Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: Results of a placebo-controlled 12-month prospective study

Acta Dermato-Venereologica

Volumn 88, Issue 5, 2008, Pages 474-479

  Hartmann, Anke ^a,b   Bröcker, Eva Bettina ^a   Hamm, Henning ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Calcineurin inhibitors; DLQI; Occlusive dressings; Tacrolimus; Vitiligo

Indexed keywords

CORTICOSTEROID; PLACEBO; TACROLIMUS;

ADULT; AGED; ARM; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FACE; FEMALE; FLUSHING; FOLLICULITIS; FOOT; HAND; HEAT INTOLERANCE; HUMAN; HYDROCOLLOID; LEG; LOWER LEG; MALE; NECK; OCCLUSIVE DRESSING; OINTMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SIDE EFFECT; SKIN ATROPHY; SKIN INFECTION; SKIN PIGMENTATION; TELANGIECTASIA; TREATMENT OUTCOME; VITILIGO;

ADULT; ANTIBODIES; ANTIBODIES, ANTINUCLEAR; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; MALE; OCCLUSIVE DRESSINGS; OINTMENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TACROLIMUS; THYROID GLAND; THYROXINE; VITILIGO;

EID: 53349097908     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0464     Document Type: Article

References (30)

1. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
2. Njoo MD, Westerhof W, Bos JD, Bossuyt PM. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998; 134: 1543-1549.
3. Hartmann A, Brocker EB, Hamm H. Repigmentation of depigmented hairs in stable vitiligo by transplantation of autologous melanocytes in fibrin suspension. J Eur Acad Derm Venereol 2008; 22: 624-626.
4. Hartmann A, Lurz C, Hamm H, Brocker EB, Hofmann UB. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005; 44: 736-742.
5. Tjoe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol 2002; 82: 369-372.
6. Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107.
7. Palter AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, et at. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810-822.
8. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19: 119-137.
9. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-585.
10. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
11. Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51: 760-766.
12. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
13. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006; 4: 942-946
14. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142: 927-928.
15. King RA, Oetting WS. Disorders of melanocytes. In: Freedberg IM, Eisen AZ, Wolff K, Austen F, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Dermatology in general medicine. New York: McGraw-Hill, 1999: p. 925-936.
16. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245-253.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
18. Fai D, Cassano N, Vena GA. Narrow-band UVB photo-therapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Derm Venereol 2007; 21: 916-920.
19. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-135.
20. Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy JC, Lacour JP, Ortonne JP. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-1069.
21. Berardesca E, Vignoli GP, Fideli D, Maibach H. Effect of occlusive dressings on the stratum corneum water holding capacity. Am J Med Sci 1992; 304: 25-28.
22. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996.
23. Schuppe HC, Homey B, Assmann T, Martens R, Ruzicka T. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998; 351: 832.
24. Prograf 5mg/ml. Astellas Pharma GmbH, Fachinformation, April 2006.
25. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816.
26. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289-295.
27. Ortonne JP, Schmitt D, Thivolet J. PUVA-induced repigmentation of vitiligo scanning electron microscopy of hair follicles. J Invest Dermatol 1980; 74: 40-42.
28. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97: 410-416.
29. Lan CC, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-505.
30. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003; 148: 373-374.